Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine

Joseph W. George, Mika Bessho, Tadayoshi Bessho

Research output: Contribution to journalArticle

Abstract

Gemcitabine (2′, 2′-difluorodeoxycytidine; dFdC) is a deoxycytidine analog and is used primarily against pancreatic cancer. The cytotoxicity of gemcitabine is due to the inhibition of DNA replication. However, a mechanism of removal of the incorporated dFdC is largely unknown. In this report, we discovered that nucleotide excision repair protein XPF-ERCC1 participates in the repair of gemcitabine-induced DNA damage and inactivation of XPF sensitizes cells to gemcitabine. Further analysis identified that XPF-ERCC1 functions together with apurinic/apyrimidinic endonuclease (APE) in the repair of gemcitabine-induced DNA damage. Our results demonstrate the importance of the evaluation of DNA repair activities in gemcitabine treatment.

Original languageEnglish (US)
Article number6357609
JournalJournal of Nucleic Acids
Volume2019
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Fingerprint Dive into the research topics of 'Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine'. Together they form a unique fingerprint.

  • Cite this